Cencora Beats Revenue and EPS Estimates as Quarterly Sales Reach $88.4 Billion

Cencora (NYSE: COR) reported fiscal fourth-quarter revenue of $88.4 billion, above the $87.9 billion analysts expected, and adjusted diluted EPS of $4.66 against the $4.57 average analyst estimate, in an 8-K accepted Wednesday, Nov. 4, 2026. Revenue rose 5.5 percent from a year earlier.

On a GAAP basis, diluted EPS was $2.71, compared with a loss of $1.75 a year earlier. Adjusted diluted EPS rose 21.4 percent from $3.84.

For the full fiscal year ended Sept. 30, revenue rose 5.0 percent to $337.4 billion. Adjusted diluted EPS was $17.97, against an average analyst estimate of $17.88. GAAP diluted EPS was $17.95, up from $7.96.

Segment results

U.S. Healthcare Solutions revenue rose 5.4 percent to $78.3 billion in the quarter, driven by unit volume growth, including specialty products and GLP-1 products. Segment operating income was $997.6 million, up 22.0 percent, which the company attributed in part to the February 2026 acquisition of OneOncology.

International Healthcare Solutions revenue rose 5.1 percent to $7.8 billion, and segment operating income rose 16.4 percent to $152.1 million. Adjusted gross profit was 4.04 percent of revenue, up 57 basis points from a year earlier, though the company said growth in GLP-1 sales, which carry lower margins, offset part of that gain.

Fiscal 2027 outlook and capital returns

Cencora expects fiscal 2027 adjusted diluted EPS of $19.40 to $19.75, growth of 8 to 10 percent. The company guided revenue growth of 3 to 5 percent and adjusted operating income growth of 4 to 6 percent. The EPS range sits just below the $19.76 average analyst estimate for fiscal 2027.

The company declared a quarterly dividend of $0.66 per share, a 10 percent increase from $0.60, payable Nov. 30 to holders of record on Nov. 13. It also introduced new reportable segments starting in the first quarter of fiscal 2027 and said it has signed a definitive agreement to acquire American Oncology Network.

Shares

Cencora's last close before the filing was $340.50 on Tuesday, Nov. 3, 2026, a market value of about $65.0 billion.